Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ester Del Signore

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Clinical Lung Cancer|December 25, 2021
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literatureChiara Catania, Bharathi Muthusamy, Gianluca Spitaleri, et al.
Expert Opinion on Therapeutic Targets|March 27, 2012
Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancerBruno Gori, Serena Ricciardi, Ester del Signore, et al.
Future Oncology (London, England)|June 1, 2012
New oral multitargeted antiangiogenics in non-small-cell lung cancer treatmentBruno Gori, Serena Ricciardi, Alberto Fulvi, et al.
Clinical Lung Cancer|June 24, 2014
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysisAntonio Passaro, Massimo Di Maio, Ester Del Signore, et al.
Therapeutics and Clinical Risk Management|January 14, 2012
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondBruno Gori, Serena Ricciardi, Alberto Fulvi, et al.
Recenti Progressi in Medicina|April 20, 2016
[Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances]Alessia Pochesci, Antonio Passaro, Chiara Catania, et al.
Journal of Thoracic Disease|April 15, 2016
Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?Antonio Passaro, Alessia Pochesci, Gianluca Spitaleri, et al.
Expert Review of Clinical Pharmacology|September 15, 2016
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the dataAntonio Passaro, Alessia Pochesci, Gianluca Spitaleri, et al.
Cancers|October 28, 2023
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and LimitationsIlaria Attili, Carla Corvaja, Gianluca Spitaleri, et al.
Cancer Treatment Reviews|July 23, 2023
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic reviewIlaria Attili, Antonio Passaro, Carla Corvaja, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Clinical Lung Cancer|December 25, 2021
The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literatureChiara Catania, Bharathi Muthusamy, Gianluca Spitaleri, et al.
Expert Opinion on Therapeutic Targets|March 27, 2012
Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancerBruno Gori, Serena Ricciardi, Ester del Signore, et al.
Future Oncology (London, England)|June 1, 2012
New oral multitargeted antiangiogenics in non-small-cell lung cancer treatmentBruno Gori, Serena Ricciardi, Alberto Fulvi, et al.
Clinical Lung Cancer|June 24, 2014
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysisAntonio Passaro, Massimo Di Maio, Ester Del Signore, et al.
Therapeutics and Clinical Risk Management|January 14, 2012
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyondBruno Gori, Serena Ricciardi, Alberto Fulvi, et al.
Recenti Progressi in Medicina|April 20, 2016
[Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances]Alessia Pochesci, Antonio Passaro, Chiara Catania, et al.
Journal of Thoracic Disease|April 15, 2016
Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?Antonio Passaro, Alessia Pochesci, Gianluca Spitaleri, et al.
Expert Review of Clinical Pharmacology|September 15, 2016
Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the dataAntonio Passaro, Alessia Pochesci, Gianluca Spitaleri, et al.
Cancers|October 28, 2023
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and LimitationsIlaria Attili, Carla Corvaja, Gianluca Spitaleri, et al.
Cancer Treatment Reviews|July 23, 2023
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic reviewIlaria Attili, Antonio Passaro, Carla Corvaja, et al.
Pageof 4